and Human Services
9000 Rockville Pike
Bethesda, Maryland 20892
This Program Announcement expires on April 15, 2004, unless reissued. DRUG ABUSE HEALTH SERVICES RESEARCH Release Date: May 21, 2001 PA NUMBER: PA-01-097 National Institute on Drug Abuse (http://www.nida.nih.gov) THIS PROGRAM ANNOUNCEMENT (PA) USES THE "MODULAR GRANT" AND "JUST-IN-TIME" CONCEPTS. IT INCLUDES DETAILED MODIFICATIONS TO STANDARD APPLICATION INSTRUCTIONS THAT MUST BE USED WHEN PREPARING APPLICATIONS IN RESPONSE TO THIS PA. PURPOSE This program announcement replaces in its entirety PA-94-047, Drug Abuse Health Services Research, published in the NIH Guide, Volume 23, Number 10, March 11, 1994. The health services research program of the National Institute on Drug Abuse (NIDA) includes interdisciplinary study of the structure, processes, and outcomes of drug abuse treatment, prevention, and related health services. Research is sought on the organization, management, and economics of drug abuse treatment and prevention services, and the effects of these factors on the quality, cost, access to, effectiveness, and outcomes of care for drug abuse and addictive disorders. Additionally, this announcement seeks studies that examine the impact of the integration of HIV/AIDS and other services on outcomes. Research applications focused on economics and financing of drug abuse treatment or prevention should also refer to PA-01-013 for information on research sought in those areas. HEALTHY PEOPLE 2010 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS led national activity for setting priority areas. This Program Announcement (PA), "Drug Abuse Health Services Research," is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople/. ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and nonprofit, and public and private organizations such as universities, colleges, hospitals, units of state or local governments, and eligible agencies of the federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. MECHANISM OF SUPPORT This PA will use the National Institutes of Health (NIH) research project (R01), small (R03), exploratory/developmental (R21), and resource-related research project (R24) award mechanisms. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total project years for an application submitted in response to this PA may not exceed five years for the R01 or R24 (see http://grants.nih.gov/grants/guide/pa-files/PAR-00-008.html), two years for the R03 (see http://grants.nih.gov/grants/guide/pa-files/PAR-00-059.html), and three years for the R21 (see http://grants.nih.gov/grants/guide/pa-files/PA-01-012.html). RESEARCH OBJECTIVES The goal of health services research is to benefit the public health by improving the quality, efficiency, and effectiveness of drug abuse prevention and treatment through a better understanding of program and system structures, processes, and outcomes. A significant goal of NIDA’s health services research program is to improve the process of blending evidence-based drug abuse prevention and treatment interventions into practice by supporting studies of transfer of knowledge, organizational adaptation, and the economics of new interventions and business practices. Topics that are of particular interest to NIDA which cut across various prevention and treatment services research domains include studies on identified subgroups (e.g., HIV/AIDS and other infectious diseases, interventions aimed at reducing health disparities among minority populations, gender-sensitive programming, children and adolescents, the elderly, drug abusers involved with the criminal justice system, and persons with co- occurring disorders), studies to learn how to match appropriate interventions to individual needs, studies of program- or system-level prevention and treatment processes, research to integrate or link drug abuse prevention or treatment to other health and social services, and research to develop instrumentation and methodology. Investigators interested in studying behavioral therapies development should refer to PA-99-107, "Behavioral Therapies Development Program." Background The Institute of Medicine (IOM) defines health services research as a multidisciplinary field of inquiry, both basic and applied, that examines the use, costs, quality, accessibility, delivery, organization, financing, and outcomes of health care services to increase knowledge and understanding of the structure, processes, and effects of health services for individuals and populations (IOM, 1995). Over the past 25 years, health services research has contributed a substantial body of knowledge on the effectiveness of drug abuse treatment and on the relationship of program and patient characteristics to treatment processes and outcomes. More recently, economics research has contributed to understanding issues related to parity, cost-effectiveness and cost benefits, and managed care. Organizational research to date has focused primarily on the structure of treatment and is just beginning to apply models of organizational change to the domains of drug abuse treatment and prevention. Many proven drug abuse prevention and treatment interventions have not been integrated into everyday practice. There is a great need to better understand how to use research findings to improve the effectiveness and efficiency of drug abuse interventions as usually delivered. Research is needed on decision processes in adopting new business and therapeutic processes (i.e., new technology and treatments), as well as on the efficient and effective implementation of new practices. Outside the laboratory, drug abuse treatment and prevention interventions are delivered within a complex environment that affects the quality, availability, or utilization of services, including funding and regulatory constraints, cultural considerations, and community infrastructure and priorities. The effects of these contextual factors on drug abuse prevention and treatment services needs to be better understood. Research is encouraged under this PA to improve the process of blending evidence-based drug abuse treatment and prevention interventions into widespread practice. Investigators are encouraged to utilize the most rigorous research design and methodology consistent with the purposes of the research study. Timely reporting of findings, including facilitating practitioner access to findings is encouraged. Research Areas The following are illustrative of major health services research areas that may be addressed under this announcement. These examples are not exhaustive, and topics not mentioned should not be considered excluded under this PA. Effectiveness. Research to improve the effectiveness of drug abuse prevention and treatment services is encouraged. In general, research should focus on understanding how and why these service systems work, rather than on whether they work. Use of theoretical models is encouraged. Areas of research interest include: o Improving prevention and treatment adherence, retention, completion, and outcomes. o Understanding how elements of prevention act alone or in combination to retard transition to drug use and abuse. o Improving the effectiveness and efficiency of services within and across program environments. o Improving how needs for services and resources are identified and met, especially for types of organizations, models of treatment, and recovery stages or processes. o Improving the effectiveness of continuity of care and aftercare treatment service models. Organization. Organizational factors, both structural (e.g., size, shape, charter) and environmental (e.g., climate, culture, resources), can affect service efficiency and effectiveness. Research is sought to improve how drug abuse treatment and prevention services and service delivery systems are organized, particularly in the contexts of continuity of care, availability and quality of services, utilization patterns, and health outcomes. Research is needed on how organizations structure and manage prevention and treatment services, and on how drug abuse service organizations interact with other health, mental health, and social services delivery agencies to meet the needs of at-risk or drug using populations. Research is especially sought on processes of organizational change through which clinical and business practices are improved. Areas of research interest include: o Organizational models that optimize service availability, access, utilization, quality, and patient outcomes, both for general prevention and treatment populations and for specific treatment subgroups, including models for integrating or linking drug treatment with mental health or medical care. o Program policies, guidelines, and procedures that improve treatment entry, engagement, retention, satisfaction, and outcomes. o Inter and intra-organizational configurations (e.g., organizational relationships, organizational size and complexity, staff diversity) related to efficiency and quality of care. o Standards of care and/or performance indicators to improve assessment of patient progress and outcomes. o Organizational models of drug abuse treatment and prevention for alternative concepts of abuse and addiction. Management. Management research is concerned with improving the effectiveness and efficiency of work practices, both those involved in delivering therapeutic services and those of managing the services delivery business. The synergy between business and therapeutic practices has received little attention in health services research on drug abuse treatment and prevention. Research on management strategies and models to improve drug abuse prevention and treatment services is encouraged. Areas of research interest include: o Management strategies to improve the adaptation and adoption of emerging or underutilized proven service delivery technologies (e.g., work team models, quality management). o Process models for the delivery of prevention and treatment services, and how these interact with or inform business practices and therapeutic processes. o Effects of various management models on organizational capacity to use resources and adapt to changes in programs, systems, or environments. o Effectiveness and cost-effectiveness of human resources management practices for service delivery personnel, such as selection methods, staff credentialing, training, continuing education, supervision, and incentives. o Business processes and their influence on service provider job performance, quality of care, and other aspects of prevention and treatment. o Therapeutic processes, and how the service provider implements, monitors, and manages these processes to maintain or improve their effectiveness. Blending Research and Practice. Research is encouraged under this PA to improve the processes of blending evidence-based drug abuse treatment interventions into clinical practice, and of bringing new prevention strategies into wider use. Areas of emphasis include studies of effective transfer of knowledge, changing organizational behavior, and financing new treatments and prevention programs. Areas of research interest include: o Technology transfer and knowledge dissemination within the context of drug abuse treatment and prevention. Research on treatment providers, including identification of needs, skills, and competencies. o Alternative models for systematic organizational change; clinical or organizational decision-making processes; models for defining, monitoring, and evaluating program performance; and integrating research-based interventions into usual treatment practices or setting; research on impact of adopting new practices on management, organizational structure, and financing. o Decision-making processes to approve new treatment services, approaches, or interventions for reimbursement by payers. Research on the impact of managed care on utilization of research-based treatment interventions. Economic Research. Economic research informs decisions related to resource allocation and improvement of efficiency and equity. Studies are sought on the economics of drug abuse services for treatment and prevention, especially for research on alternative payment systems, public and private financing systems, and the design of insurance. Illustrative areas of research include financing of drug abuse treatment and prevention services, alternative delivery systems and managed care, cost-benefit, cost-effectiveness, and cost- utility analysis, and cost and production of drug treatment and prevention services. More information on NIDA’s program of research on the economics of drug abuse prevention or treatment is available in PA-01-013. Access and Utilization of Drug Abuse Treatment Services. Particularly for underserved subgroups, research is sought on access to and utilization of drug abuse prevention and treatment services. This includes (a) studies of treatment integration and linkage models to improve access to and utilization of medical, psychiatric, and social services; (b) research on individual, program-level, and environmental barriers to treatment; and (c) studies of the natural history of utilization of drug abuse treatment and related health services (e.g., treatment careers, effectiveness and cost benefits of repeated episodes of treatment). Cross-Cutting Research Areas. Areas of health services research that cut across the topical areas suggested above include: o Special populations. Health services research studies focused on treatment and prevention services in specific populations, including persons with HIV/AIDS, gender-sensitive programming, children and adolescents, patients with multiple co-occurring disorders, the homeless, ethnic minorities, and the elderly. Studies of treatment services provided to criminal justice involved drug abusers, including diversion programs, judicially mandated treatment for drug abuse, and continuity of care/transition models for drug abusing offenders. Research on health disparities resulting from problems of access, utilization, or effectiveness of prevention or treatment interventions. o Intervention matching. Studies to deliver defined prevention and treatment interventions and services more effectively and efficiently, and to investigate the contribution of discrete intervention elements to processes and outcomes. Research to improve the assessment of patient needs and to match needs with treatment settings, services, and resources. Research on stages or phases of treatment to identify and match services to client recovery stage. Studies of continuity of care and aftercare models that match services to patient needs. o Quality of drug abuse prevention and treatment. Studies to improve the quality of drug abuse treatment and prevention services, including range and accessibility of services, service mix, referral systems, and competence of staff; research on customer expectations, perceptions, and satisfaction with services. Studies of prevention and treatment processes to investigate the contribution of discrete intervention elements to outcome, to improve prevention and treatment interventions in established settings, or to improve clinical and organizational decision-making or criteria formulation. (Investigators interested in behavioral therapy processes should also see PA- 99-107, "Behavioral Therapies Development Program.") o Research instrumentation and methodology. Development of research instruments and methods to study the effectiveness of drug abuse treatment, to study treatment processes, and to develop patient-treatment services matching protocols. Measurement of the effectiveness of prevention interventions. Development and validation of measures of drug use and addiction severity, system-level needs and outcomes, and quality of care indicators. Development of instrumentation and methodology to assess community prevention needs, help quantify severity of community drug problems, and improve subgroup receptivity to prevention messages. Measurement of organizational factors and relationships between organizational entities such as treatment agencies and other health, social services, and criminal justice system agencies. Infrastructure Development Grants. Applications for Infrastructure Development grants use the Resource-Related Research Projects (R24) mechanism. Infrastructure Development grants are intended to improve infrastructure and capability to carry out health services research, especially in areas of organization, management, and economics. Infrastructure Development grants are limited to $300,000 in direct costs per year. The applicant should describe plans to develop the institutional research infrastructure and faculty capacity to conduct drug abuse services research. Two components are required: an Infrastructure Improvement Plan and Research Pilot Proposals. o Infrastructure Improvement Plan. Infrastructure Development applicants must identify specific needs and explain how these will be addressed under the Infrastructure Development award. The Infrastructure Improvement Plan may request salary costs of core personnel and support for student research assistants, shared research resource costs such as consultation and equipment, support of pilot studies, and other necessary implementation costs. o Research Pilot Proposals. Infrastructure Development applicants should include at least two research pilot proposals. Pilots are intended to be developmental or training projects with the potential to lead to research of high scientific and technical merit. A budget must accompany each proposed pilot. Investigators interested in developing or improving infrastructure in Social Work should also refer to NIDA’s PAR-00-008, "Social Work Research Development Program." INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the UPDATED "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research," published in the NIH Guide for Grants and Contracts on August 2, 2000 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html); a complete copy of the updated Guidelines is available at http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm. The revisions relate to NIH defined Phase III clinical trials and require: a) all applications or proposals and/or protocols to provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) all investigators to report accrual, and to conduct and report analyses, as appropriate, by sex/gender and/or racial/ethnic group differences. NIH POLICY AND GUIDELINES ON THE INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of NIH that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them. This policy applies to all initial (Type 1) applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects" that was published in the NIH Guide for Grants and Contracts, March 6, 1998, and is available at the following URL address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html. URLS IN NIH GRANT APPLICATIONS OR APPENDICES All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Reviewers are cautioned that their anonymity may be compromised when they directly access an Internet site. NATIONAL ADVISORY COUNCIL ON DRUG ABUSE RECOMMENDED GUIDELINES FOR THE ADMINISTRATION OF DRUGS TO HUMAN SUBJECTS The National Advisory Council on Drug Abuse recognizes the importance of research involving the administration of drugs to human subjects and has developed guidelines relevant to such research. Potential applicants are encouraged to obtain and review the recommendations of the Council before submitting an application that will administer compounds to human subjects. The guidelines are available on NIDA's Home Page at http://www.nida.nih.gov under Funding or may be obtained by calling (301) 443-2755. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 4/98) and will be accepted at the standard application deadlines as indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone (301) 435- 0714, E-mail: GrantsInfo@nih.gov. Applicants planning to submit an investigator-initiated new (type 1), competing continuation (type 2), competing supplement, or any amended/revised version of the preceding grant application types requesting $500,000 or more in direct costs for any year are advised that he or she must contact the Institute or Center (IC) program staff before submitting the application; i.e., as plans for the study are being developed. Furthermore, the application must obtain agreement from the IC staff that the IC will accept the application for consideration for award. Finally, the applicant must identify, in a cover letter sent with the application, the staff member and Institute or Center who agreed to accept assignment of the application. This policy requires an applicant to obtain agreement for acceptance of both any such application and any such subsequent amendment. Refer to the NIH Guide for Grants and Contracts, March 20, 1998 at http://grants.nih.gov/grants/guide/notice-files/not98-030.html. The modular grant concept establishes specific modules in which direct costs may be requested as well as a maximum level for requested budgets. Only limited budgetary information is required under this approach. The just-in-time concept allows applicants to submit certain information only when there is a possibility for an award. It is anticipated that these changes will reduce the administrative burden for the applicants, reviewers, and Institute staff. The research grant application form PHS 398 (rev. 4/98) is to be used in applying for these grants, with the modifications noted below. SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS BUDGET INSTRUCTIONS Modular Grant applications will request direct costs in $25,000 modules, up to a total direct cost request of $250,000 per year. The total direct costs must be requested in accordance with the program guidelines and the modifications made to the standard PHS 398 application instructions described below: PHS 398 o FACE PAGE - Items 7a and 7b should be completed, indicating Direct Costs (in $25,000 increments up to a maximum of $250,000) and Total Costs [Modular Total Direct plus Facilities and Administrative (F&A;) costs] for the initial budget period. Items 8a and 8b should be completed indicating the Direct and Total Costs for the entire proposed period of support. o DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD - Do not complete Form Page 4 of the PHS 398. It is not required and will not be accepted with the application. o BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT - Do not complete the categorical budget table on Form Page 5 of the PHS 398. It is not required and will not be accepted with the application. o NARRATIVE BUDGET JUSTIFICATION - Prepare a Modular Grant Budget Narrative page (see http://grants.nih.gov/grants/funding/modular/modular.htm for sample pages). At the top of the page, enter the total direct costs requested for each year. This is not a Form page. Under Personnel, list all project personnel, including their names, percent of effort, and roles on the project. No individual salary information should be provided. However, the applicant should use the NIH appropriation language salary cap and the NIH policy for graduate student compensation in developing the budget request. For Consortium/Contractual costs, provide an estimate of total costs (direct plus facilities and administrative) for each year, each rounded to the nearest $1,000. List the individuals/organizations with whom consortium or contractual arrangements have been made, the percent effort of all personnel, and role on the project. Indicate whether the collaborating institution is foreign or domestic. The total cost for a consortium/contractual arrangement is included in the overall requested modular direct cost amount. Include the Letter of Intent to establish a consortium. Provide an additional narrative budget justification for any variation in the number of modules requested. o BIOGRAPHICAL SKETCH - The Biographical Sketch provides information used by reviewers in the assessment of each individual's qualifications for a specific role in the proposed project, as well as to evaluate the overall qualifications of the research team. A biographical sketch is required for all personnel, following the instructions below. No more than three pages may be used for each person. A sample biographical sketch may be viewed at: http://grants.nih.gov/grants/funding/modular/modular.htm. - Complete the educational block at the top of the form page; - List position(s) and any honors; - Provide information, including overall goals and responsibilities, on research projects ongoing or completed during the last three years; and - List selected peer-reviewed publications with full citations. o CHECKLIST - This page should be completed and submitted with the application. If the F&A; rate agreement has been established, indicate the type of agreement and the date. All appropriate exclusions must be applied in the calculation of the F&A; costs for the initial budget period and all future budget years. The applicant should provide the name and phone number of the individual to contact concerning fiscal and administrative issues if additional information is necessary following the initial review. The title and number of the program announcement must be typed on line 2 of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the checklist, and five signed photocopies in one package to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 – MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) REVIEW CONSIDERATIONS Applications will be assigned on the basis of established NIH referral guidelines. Applications will be evaluated for scientific and technical merit by appropriate scientific review group convened by NIDA in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory board or council. Small grants do not receive a second-level review. Review Criteria The goals of NIH-supported research are to advance our understanding of biological, behavioral, and social sciences improve the control of disease, and enhance health. In the written comments reviewers will be asked to discuss the following aspects of the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that the application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward. (1) Significance: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? (2) Approach: Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? (3) Innovation: Does the project employ novel concepts, approaches, or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? (4) Investigator: Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? (5) Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? For Research Infrastructure (R24) grants, the following review criteria apply: Infrastructure Improvement Plan - The quality and potential of the plan to develop a sustainable research program in one or more core substantive areas of drug abuse health services research; - The quality and appropriateness of the proposed plans for the development of the research team; - The potential of the project's management organization and proposed research team to become leaders in the field of drug abuse health services research and to improve the environment for collaborative drug abuse research; and - The scientific leadership, experience, and appropriateness of the Program Director for the implementation of the Infrastructure Development grant. Research Pilot Projects - The potential of the study to be a building block in the development of future research; - The innovation and creativity of the approach in addressing a core health services research problem; - The qualifications of the team leader and the research team; and - The feasibility of the proposed research design, methods, and analyses in relation to the aims of a pilot project. In addition to the above criteria, in accordance with NIH policy, all applications will also be reviewed with respect to the following: o The adequacy of plans to include both genders, minorities and their subgroups, and children as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. o The reasonableness of the proposed budget and duration in relation to the proposed research. o The adequacy of the proposed protection for humans, animals, or the environment, to the extent they may be adversely affected by the project proposed in the application. AWARD CRITERIA Applications will compete for available funds with all other recommended applications. The following will be considered in making funding decisions: Quality of the proposed project as determined by peer review, availability of funds, and program priority. INQUIRIES Inquiries are encouraged. The opportunity to clarify issues or questions from potential applicants is welcomed. Direct inquiries regarding programmatic issues related to treatment to: Jerry Flanzer, D.S.W. Acting Chief, Services Research Branch Division of Epidemiology, Services, and Prevention Research National Institute on Drug Abuse 6001 Executive Boulevard, Room 4222, MSC 9565 Bethesda, MD 20892-9565 Telephone: (301) 443-4060 Fax: (301) 443-6815 E-mail: jf199i@nih.gov Direct inquiries regarding programmatic issues related to prevention to: Elizabeth Robertson, Ph.D. Chief, Prevention Research Branch Division of Epidemiology, Services, and Prevention Research National Institute on Drug Abuse 6001 Executive Boulevard, Room 5154, MSC 9589 Bethesda, MD 20892- 9589 Telephone: (301) 443-1514 Fax: (301) 480-2542 E-mail: er52h@nih.gov Direct inquiries regarding review issues to: Teresa Levitin, Ph.D. Office of Extramural Affairs National Institute on Drug Abuse 6001 Executive Boulevard, Room 3158, MSC 9547 Bethesda, MD 20892-9547 Telephone: (301) 443-2755 Fax: (301) 443-0538 E-mail: tl25u@nih.gov Direct inquiries regarding fiscal matters to: Gary Fleming, J.D., M.A. Grants Management Branch Office of Planning and Resource Management National Institute on Drug Abuse 6001 Executive Boulevard, Room 3131, MSC 9541 Bethesda, MD 20892-9541 Telephone: (301) 443-6710 Fax: (301) 594-6847 E-mail: gf6s@nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.279. Awards are made under authorization of sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and administered under NIH grants policies and Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
|
|
Department of Health and Human Services |
|
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |